Article Information
PMID
Published By
Print ISSN
1109-6535
Online ISSN
1790-6245
History
- August 18, 2008
- September 2, 2008
- Published online September 1, 2008.
Copyright & License
Copyright © 2008 The Author(s). Published by the International Institute of Anticancer Research.
Author Information
- 1Institute for Experimental Oncology, Oncotest GmbH, Freiburg, Germany
- 2Clinic of Urology, University of Geneva, Switzerland
- 3Tumor Biology Center at the University of Freiburg, Clinic for Medical Oncology, Freiburg, Germany
- 4Barbara Ann Karmanos Cancer Institute and Department of Pharmacology, Wayne State University School of Medicine, Detroit, MI, U.S.A.
- Correspondence to: Dr. Angelika M. Burger, Hudson-Webber Cancer Research Center, Rm 640.2 Barbara Ann Karmanos Cancer Institute, Detroit, MI 48201, U.S.A. Tel: +1 313 576 8302, Fax: +1 313 576 9417, e-mail: amburger{at}wayne.edu / Dr. Victoria Smith, Oncotest GmbH, Am Flughafen 12-14, D-79108 Freiburg, Germany. e-mail: Vicki.Smith{at}oncotest.de
Statistics from Altmetric.com
Cited By...
In this issue
Jump to section
Related Articles
Cited By...
- Ex Vivo Testing of Patient-Derived Xenografts Mirrors the Clinical Outcome of Patients with Pancreatic Ductal Adenocarcinoma
- Activation of Epidermal Growth Factor Receptor/p38/Hypoxia-inducible Factor-1{alpha} Is Pivotal for Angiogenesis and Tumorigenesis of Malignantly Transformed Cells Induced by Hexavalent Chromium
- ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat
- Llama-derived Single Variable Domains (Nanobodies) Directed against Chemokine Receptor CXCR7 Reduce Head and Neck Cancer Cell Growth in Vivo